---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-035922"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2026-08-04T11:05:28+00:00"
generated_at: "2026-08-04T11:10:24.495727+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Elite Pharmaceuticals launches generic Requip XL; addresses $10M U.S. market

## Summary
- Launched generic Ropinirole Extended-Release Tablets (2, 4, 6, 8, 12 mg) for Parkinson's disease.
- Product marketed under Elite Laboratories label; branded Requip XL and equivalents had $10M U.S. sales (IQVIA, 12 months ending June 2026).
- Expands Elite's niche generic portfolio; company operates cGMP/DEA-registered facility in Northvale, NJ.

## SEC filing metadata
- accession: 0001493152-26-035922
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2026-08-04T11:05:28+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315226035922/0001493152-26-035922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315226035922/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-035922
- JSON: https://secwatch.observer/filing/0001493152-26-035922.json
- Plain text: https://secwatch.observer/filing/0001493152-26-035922.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.